Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2002
10/03/2002WO2002077155A2 Keratinocyte growth factor-2
10/03/2002WO2002077154A2 Gene delivery device and gene delivery method
10/03/2002WO2002077034A2 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
10/03/2002WO2002077033A1 Antibodies against cancer
10/03/2002WO2002077027A1 Human stra6-like protein and nucleic acids encoding the same
10/03/2002WO2002077026A2 Gene involved in v(d)j recombination and/or dna repair
10/03/2002WO2002077023A2 A new essential downstream component of the wingless signalling pathway
10/03/2002WO2002076508A1 Methods for delivering nucleic acid molecules into cells and assessment thereof
10/03/2002WO2002076507A2 Uses of opg ligand to modulate immune responses
10/03/2002WO2002076494A2 USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
10/03/2002WO2002076482A2 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
10/03/2002WO2002076468A1 Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
10/03/2002WO2002076435A2 Lipid profile modulation with steroids
10/03/2002WO2002076427A2 Ph sensitive liposomal drug delivery
10/03/2002WO2002076394A2 Enzyme-based anti-cancer compositions and methods
10/03/2002WO2002076216A1 Viral vectors and their use in therapeutic methods
10/03/2002WO2002059153A3 Anticoagulants and their uses
10/03/2002WO2002058728A3 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses
10/03/2002WO2002057424A3 Nucleic acid delivery formulations
10/03/2002WO2002056828A3 Helper virus-free herpes virus amplicon particles and uses thereof
10/03/2002WO2002055109A3 Generation and/or reduction of new lung tissue in an affected lung, by modulation of the wnt-pathway
10/03/2002WO2002029086A3 Nucleic acid sequences differentially expressed in cancer tissue
10/03/2002WO2002029073A3 Gene delivery vectors for stem cells
10/03/2002WO2002026193A3 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
10/03/2002WO2002022657A3 Peptide antagonist of multiple chemokine receptors and uses thereof
10/03/2002WO2002018407A3 Antisense oligonucleotides against vanilloid receptor 1
10/03/2002WO2002000242A3 Human papilloma virus treatment
10/03/2002WO2001098515A3 Gene-regulating conjugates
10/03/2002WO2001098355A3 Cgi-69 compositions and methods of use
10/03/2002WO2001096388A3 Compositions and methods for the therapy and diagnosis of colon cancer
10/03/2002WO2001093836A3 Encapsulation of polynucleotides and drugs into targeted liposomes
10/03/2002WO2001021812A9 Phosphatases which activate map kinase pathways
10/03/2002WO2000073502A3 Essential genes and gene products for identifying, developing and optimising immunological and pharmacological active ingredients for the treatment of microbial infections
10/03/2002WO2000069896A9 Molecular interactions in haematopoietic cells
10/03/2002US20020144302 Expression vector coding protein for use in the treatment of liver disorders
10/03/2002US20020144299 Nuceotide sequences coding malarial surface protein for use in the treatment and prevention of malaria
10/03/2002US20020143156 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of nervous system, vision, kidney and liver disorders
10/03/2002US20020142989 Oncolytic/immunogenic complementary-adenoviral vector system
10/03/2002US20020142987 Methods of inducing mucosal immunity
10/03/2002US20020142986 Used in the diagnosis or prognosis of liver associated disorders
10/03/2002US20020142984 Administering a positively charged liposome to animal, wherein positively charged liposome is associated with nucleic acid molecule, wherein nucleic acid molecule is in operable association with a promoter
10/03/2002US20020142983 MUC-1 antagonists and methods of treating immune disorders
10/03/2002US20020142981 Gene expression profiles in liver cancer
10/03/2002US20020142980 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
10/03/2002US20020142960 Exposing cells to an aggregate formulation which comprises VP22, or a polypeptide with transport function of VP22, and oligonucleotides or polynucleotides; exposing cells to a disaggregating agent which can promote disaggregation
10/03/2002US20020142461 T1 Receptor-like ligand II and uses thereof
10/03/2002US20020142459 Generating vascularized tissue; obtain tissue culture, mix microvessel segment, inject tissue with vascularized graft, evaluate tissue for vascularizat ion
10/03/2002US20020142458 Prevascularized constructs for implantation to provide blood perfusion
10/03/2002US20020142448 Antibody for use in the diagnosis, treatment and prevention of bone disorders and cancer
10/03/2002US20020142436 Enzymatic protein for use in the treatment of tumors, nervous system, cardiovascular, psychological, pregnancy, bone, kidney, respiratory and alimentary canal disorders
10/03/2002US20020142432 Human endosulfine gene
10/03/2002US20020142428 Novel kinases and uses thereof
10/03/2002US20020142397 Genetically engineering cell; obtain cell, incubate with cell growth factor, remove nucleus or chromatin, insert into cell, propagate cell
10/03/2002US20020142353 Connective tissue growth factor (CTGF) and methods of use
10/03/2002US20020142330 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor
10/03/2002US20020142317 Methods for the early diagnosis of ovarian cancer
10/03/2002US20020142284 Detecting kidney protective agent; obtain cells, incubate with modulator, measure nucleotide sequence expression, compare to control, monitor adjustment in nucleotide sequences expresion
10/03/2002US20020142049 Precipitating drug as solid
10/03/2002US20020141983 Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
10/03/2002US20020141982 Gene therapy methods using bone marrow-derived cells
10/03/2002US20020141981 Materials and methods for treating oncological disease
10/03/2002US20020141980 Convection-enhanced delivery of AAV vectors
10/03/2002US20020141979 Antidiabetic agents; prevent organ rejection; antiinflammatory agents
10/03/2002US20020141978 Retroviral vectors
10/03/2002CA2633522A1 Methods for delivering nucleic acid molecules into cells and assessment thereof
10/03/2002CA2442318A1 Antibodies against cancer
10/03/2002CA2442089A1 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
10/03/2002CA2442077A1 Novel nucleic acids and polypeptides
10/03/2002CA2441706A1 A new essential downstream component of the wingless signalling pathway
10/03/2002CA2441663A1 Viral vectors and their use in therapeutic methods
10/03/2002CA2441588A1 Use of cytokines of the tgf-.beta. superfamily for the treatment and diagnosis of skin related disorders
10/03/2002CA2441378A1 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
10/03/2002CA2441287A1 Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
10/03/2002CA2439678A1 Uses of opg ligand to modulate immune responses
10/03/2002CA2437287A1 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
10/03/2002CA2433458A1 Keratinocyte growth factor-2
10/03/2002CA2406527A1 Novel human stras-like protein and nucleic acids encoding the same
10/02/2002EP1245677A1 Nucleic acids and proteins of the mycoplasma hyopneumoniae mhp3 gene and uses thereof
10/02/2002EP1245673A2 Efficient genetic suppressor elements
10/02/2002EP1245249A2 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug
10/02/2002EP1244807A1 Il-6 like polynucleotide
10/02/2002EP1244805A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes
10/02/2002EP1244798A2 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
10/02/2002EP1244793A2 Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
10/02/2002EP1244790A2 Nucleic acids encoding polypeptides having chips activity
10/02/2002EP1244789A2 Genes identified as required for proliferation of e. coli
10/02/2002EP1244785A1 Mus101 and homologues thereof
10/02/2002EP1244781A2 Antisense oligonucleotides
10/02/2002EP1244780A2 Dna encoding the human serine protease t
10/02/2002EP1244778A2 Human heparanase-related polypeptide and nucleic acid
10/02/2002EP1244774A2 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same
10/02/2002EP1244773A1 Mutated hepatitis b virus, its nucleic and protein constituents and uses thereof
10/02/2002EP1244705A2 Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
10/02/2002EP1244701A1 Transferrin polynucleotides, polypeptides, and antibodies
10/02/2002EP1244699A2 Educational kit and method using tumor necrosis factor-stimulated gene and protein
10/02/2002EP1244698A2 Novel human transporter proteins and polynucleotides encoding the same
10/02/2002EP1244689A2 Cytokine polypeptides and nucleic acids
10/02/2002EP1244688A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
10/02/2002EP1244686A1 Transforming growth factor alpha hiii
10/02/2002EP1244685A1 Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies
1 ... 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 ... 870